(Q38375982)

2 September 2017

1 reference

title

Nanocarrier-based interventions for the management of MDR/XDR-TB. (English)

1 reference

2 September 2017

1 reference

Sanaul Mustafa

1

1 reference

2 September 2017

Roopa S Pai

series ordinal

2

1 reference

2 September 2017

Gurinder Singh

series ordinal

3

1 reference

2 September 2017

V Kusum Devi

series ordinal

4

1 reference

2 September 2017

publication date

13 March 2015

1 reference

Journal of Drug Targeting

2 September 2017

published in

1 reference

2 September 2017

volume

23

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

287-304

1 reference

The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Multiresistant tuberculosis in Brazil: history and control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Genetic basis of isoniazid resistance of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Catalase expression, katG, and MIC of isoniazid for Mycobacterium tuberculosis isolates from São Paulo, Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Presence of katG gene in resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Genetics of drug resistance in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Molecular genetics of drug resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

The emergence of drug-resistant tuberculosis in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Fluoroquinolones, tuberculosis, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Characterization of the KstR-dependent promoter of the gene for the first step of the cholesterol degradative pathway in Mycobacterium smegmatis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Molecular insights into aminoglycoside action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

A balancing act: efflux/influx in mycobacterial drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Cost-effectiveness of treating multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Clinical and operational value of the extensively drug-resistant tuberculosis definition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Epidemiology and clinical management of XDR-TB: a systematic review by TBNET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Pulmonary resection in the treatment of multidrug-resistant tuberculosis: a retrospective study of 56 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Comprehensive treatment of extensively drug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Proposed molecular and cellular mechanism for aminoglycoside ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

A study of amikacin given once versus twice daily in serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Pharmaceutical characterization of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine used for the treatment of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Tuberculosis chemotherapy: current drug delivery approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nanoparticle-based targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Clinical perspectives on pulmonary systemic and macromolecular delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

The near future: improving the activity of rifamycins and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Niosomal encapsulation of the antitubercular drug, pyrazinamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

From innovative polymers to advanced nanomedicine: key challenges, recent progress and future perspectives: the second Symposium on Innovative Polymers for Controlled Delivery Suzhou, China, 11–14 September 2012 .

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Drug delivery and nanoparticles:applications and hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Current development and future prospects in chemotherapy of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

New antituberculous drugs in development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

The potential of azole antifungals against latent/persistent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Fullerene isoniazid conjugate--a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Formulation and evaluation of a salted-out isoniazid-loaded nanosystem

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

Advances and challenges of nanotechnology-based drug delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1009076

10.3109/1061186X.2015.1009076

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference